Breaking News Instant updates and real-time market news.

VZ

Verizon

, LOGI

Logitech

$37.58

0.25 (0.67%)

09:17
01/23/18
01/23
09:17
01/23/18
09:17

On The Fly: Pre-market Movers

UP AFTER EARNINGS: Verizon (VZ), up 3.3%... Logitech (LOGI), up 6.2%... Johnson & Johnson (JNJ), up marginally... Netflix (NFLX), up 10.5%... Huntington Bancshares (HBAN), up just under 1%... Travelers (TRV), up 3.3%... Kimberly Clark (KMB), up 1.8%... ResMed (RMD), up 10.3%... TD Ameritrade (AMTD), up 3.4%... Allegheny Technologies (ATI), up 5.4%. ALSO HIGHER: Tesla (TSLA), up 2.8% after announcing CEO Elon Musk's new performance-based compensation plan... Apple (AAPL), up marginally after announcing the order and arrival dates of the HomePod. LOWER: Procter & Gamble (PG), down 1.7% after reporting quarterly resutls... Adamas Pharmaceuticals (ADMS), down 6.2% after filing to sell $85M in common stock... GoPro (GPRO), down 6% after being downgraded to Underweight from Equal Weight at Morgan Stanley... Twitter (TWTR), down 3.6% after announcing the departure of COO Anthony Noto.

VZ

Verizon

LOGI

Logitech

$37.58

0.25 (0.67%)

JNJ

Johnson & Johnson

NFLX

Netflix

$227.58

7.12 (3.23%)

HBAN

Huntington Bancshares

$16.03

0.22 (1.39%)

KMB

Kimberly-Clark

RMD

ResMed

AMTD

TD Ameritrade

$55.88

0.71 (1.29%)

ATI

Allegheny Technologies

TSLA

Tesla

$351.56

1.54 (0.44%)

AAPL

Apple

$177.00

-1.46 (-0.82%)

PG

Procter & Gamble

ADMS

Adamas Pharmaceuticals

$40.79

2.6 (6.81%)

GPRO

GoPro

$6.30

0.01 (0.16%)

TWTR

Twitter

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 30

    Jan

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 08

    Feb

  • 16

    Feb

  • 16

    Feb

  • 28

    Feb

  • 08

    Mar

  • 24

    Jan

VZ Verizon

01/17/18
01/17/18
DOWNGRADE
Target $55

Equal Weight
With fewer likely buyers seen, Morgan Stanley cuts Dish to Equal Weight
As previously reported, Morgan Stanley analyst Benjamin Swinburne downgraded Dish Network (DISH) to Equal Weight from Overweight as he now sees fewer likely buyers of its assets than hoped. T-Mobile (TMUS) has acquired significant additional spectrum, reducing the potential for a Dish partnership, tax reform will help Verizon (VZ) as it moves further towards small cell deployments in lieu of adding new spectrum, and the FCC is also considering a new auction, Swinburne tells investors. Additionally, the DOJ challenge of AT&T's (T) Time Warner (TWX) deal suggests a more challenging M&A backdrop than assumed for AT&T, which he had viewed as potentially the most logical buyer of Dish's DBS assets, Swinburne added. With Dish beginning to spend on its network in 2018 to boot, Swinburne lowered his price target on the stock to $55 from $75.
01/22/18
HOWW
01/22/18
UPGRADE
HOWW
Outperform
Verizon upgraded to Outperform from Sector Perform at Scotia Howard Weil
01/22/18
01/22/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. U.S. Steel (X) upgraded to Neutral from Sell at Citi with analyst Alexander Hacking saying he sees steel prices better supported near-term and increased his EBITDA estimates. 2. Aflac (AFL) upgraded to Strong Buy from Outperform at Raymond James with analyst Gregory Peters citing relative shares underperformance since the recent article alleging fraud at the company. 3. Schlumberger (SLB) upgraded to Overweight from Neutral at Atlantic Equities. 4. Harley-Davidson (HOG) upgraded to Outperform from Market Perform at Wells Fargo with analyst Timothy Conder saying investors are not appreciating the benefits of tax reform to Harley-Davidson. 5. Verizon (VZ) upgraded to Outperform from Sector Perform at Scotia Howard Weil. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/16/18
01/16/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) downgraded to Underperform from Neutral at Macquarie with analyst Laurent Vasilescu citing weaker North America revenues, flat Connected Fitness revenues, international revenues of up 21% year-over-year, gross margin pressure, and higher SG&A assumptions. 2. Verizon (VZ) downgraded to Neutral from Buy at MoffettNathanson. 3. Lockheed Martin (LMT) and Rockwell Collins (COL) were downgraded to Market Perform from Outperform at Wells Fargo. 4. Spirit Airlines (SAVE) downgraded to Hold from Buy at Stifel with analyst Joseph DeNardi saying he believes Spirit will benefit this year from an improving demand and revenue environment, but that its higher revenue risk relative to potential competitive responses to its expected capacity growth is not fully reflected in the stock at current levels. 5. Finisar (FNSR) downgraded to Sell from Neutral at Goldman Sachs with analyst Doug Clark saying risks of oversupply and competition are heating up in the optical component landscape. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
LOGI Logitech
$37.58

0.25 (0.67%)

10/25/17
LOOP
10/25/17
NO CHANGE
Target $48
LOOP
Buy
Logitech valuation at attractive levels, says Loop Capital
Loop Capital analyst Ananda Baruah says Logitech is a "secular favorite" given its "increasingly consumer cloud bent". Baruah keeps a Buy rating on the stock with a $48 price target, adding that consensus estimates over the next 1-2 years remain low as the company accelerates into normalized double-digit organic revenue growth.
07/06/17
07/06/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Nike (NKE) initiated with an Outperform at Raymond James. 2. JPMorgan (JPM) initiated with a Neutral at Goldman Sachs. 3. At Home Group (HOME) initiated with a Buy at SunTrust. 4. Logitech (LOGI) initiated with a Buy at Citi. 5. Medtronic (MDT) initiated with an Outperform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/24/17
LOOP
07/24/17
INITIATION
Target $48
LOOP
Buy
Logitech initiated with a Buy at Loop Capital
Loop Capital analyst Ananda Baruah initiated Logitech with a Buy and a $48 price target saying it is an innovative brand with increasingly consumer cloud focus. The analyst expects normalized double-digit organic revenue and earnings growth, with multiple expansion and robust free cash flow.
07/26/17
LOOP
07/26/17
NO CHANGE
Target $48
LOOP
Buy
Logitech should be bought on post-earnings pullback, says Loop Capital
Loop Capital analyst Ananda Baruah said he is "even more enthusiastic" in his Buy rating of Logitech following its June quarter report and he views the post-earnings pullback as a buying opportunity. With revenue momentum already accelerating ahead of upcoming material product launches, Baruah continues to think consensus estimates for the next 1-2 years remain low, he tells investors. He keeps a $48 price target on Logitech.
JNJ Johnson & Johnson

01/18/18
MSCO
01/18/18
NO CHANGE
Target $157
MSCO
Equal Weight
Zytiga ruling a headwind, but doesn't change J&J thesis, says Morgan Stanley
Morgan Stanley analyst David Lewis noted that Johnson & Johnson suffered an adverse Zytiga IPR ruling, which he calls an incremental headwind. However, he added that a possible earlier generic Zytiga entry is irrelevant to his net present value for J&J shares and doesn't change his view that its Pharma growth accelerates in 2018. Lewis keeps an Equal Weight rating and $157 price target on J&J shares.
01/04/18
RBCM
01/04/18
NO CHANGE
Target $54
RBCM
Outperform
Pacira price target raised to $54 from $50 at RBC Capital
RBC Capital analyst Randall Stanicky raised his price target on Pacira (PCRX) to $54 and kept his Outperform rating. Stanicky says his focus is on the company's expected pre-announcement for Q4 this week and his upcoming discussion with CEO Dave Stack on Monday regarding changes from CMS around unbundling of payments that could represent a game changing opportunity for the company's EXPAREL. The analyst notes that traction is building around Pacira's relationship with Johnson & Johnson (JNJ) on the ortho selling side, which marks about half of its revenue.
01/02/18
JPMS
01/02/18
DOWNGRADE
Target $150
JPMS
Neutral
Johnson & Johnson downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Michael Weinstein downgraded Johnson & Johnson (JNJ) to Neutral with an unchanged price target of $150. The stock closed Friday down 81c to $139.72. The analyst sees greater upside potential in other large cap names with J&J shares trading at 17.9 times his 2018 earnings estimate. He remains "fundamentally bullish" on the company, however. Weinstein this morning upgraded both Abbott Laboratories (ABT) and Baxter International (BAX) to Overweight.
01/02/18
01/02/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) downgraded to Neutral from Overweight at JPMorgan with analyst Michael Weinstein saying he sees greater upside potential in other large cap names with J&J shares trading at 17.9 times his 2018 earnings estimate. 2. PG&E (PCG) downgraded to Sell from Neutral at Guggenheim and to Neutral from Buy at Goldman Sachs. Goldman analyst Michael Lapides saying resolution of claims from the California wildfires, if inverse condemnation is applied, could take years and "cash flow/balance sheet impacts could prove significant still." 3. Allstate (ALL) downgraded to Underperform from Market Perform at Keefe Bruyette with analyst Meyer Shields saying the company's margin expansion story has played out. 4. Cabot Oil & Gas (COG) downgraded two notches to Underperform from Outperform at Raymond James with analyst John Freeman citing valuation after "considerable" 2017 share outperformance. 5. Windstream (WIN) downgraded to Underweight from Neutral at JPMorgan with analyst Philip Cusick saying he sees fundamental business challenges continuing in both the near and long term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NFLX Netflix
$227.58

7.12 (3.23%)

01/23/18
BERN
01/23/18
NO CHANGE
Target $302
BERN
Outperform
Netflix price target raised to $302 from $230 at Bernstein
Bernstein analyst Todd Juenger raised his price target for Netflix to $302 from $230 following quarterly results. The analyst reiterates an Outperform rating on the shares.
01/23/18
BUCK
01/23/18
DOWNGRADE
BUCK
Neutral
Netflix downgraded to Neutral on valuation at Buckingham
Buckingham analyst Matthew Harrigan downgraded Netflix to Neutral from Buy citing valuation and raised its price target to $257 from $251. Harrigan remains confident in Netflix's position as a global streaming leader, but contents continued share momentum depends on market confidence that Netflix's guided $3B-4B in negative 2018 free cash flow will generate superior investment returns.
01/23/18
BUCK
01/23/18
DOWNGRADE
BUCK
Neutral
Netflix downgraded to Neutral from Buy at Buckingham
01/23/18
OPCO
01/23/18
NO CHANGE
Target $285
OPCO
Outperform
Netflix price target raised to $285 from $245 at Oppenheimer
Oppenheimer analyst Jason Helfstein raised his price target for Netflix to $285 from $245 after the company reported another "strong" quarter with Q4 subscriptions above guidance and Q1 subscriptions guidance suggesting no slowdown, despite the pricing increase. The analyst reiterates an Outperform rating on the shares.
HBAN Huntington Bancshares
$16.03

0.22 (1.39%)

10/26/17
BMOC
10/26/17
DOWNGRADE
Target $14.5
BMOC
Market Perform
Huntington downgraded to Market Perform from Outperform at BMO Capital
BMO Capital analyst Lana Chan downgraded Huntington Bancshares (HBAN) to Market Perform citing slower near-term loan growth and "continued disappointment" on operating expenses following the company's Q3 results. The analyst lowered her price target for the shares to $14.50 from $15. Chan's top picks are now KeyCorp (KEY) and Signature Bank (SBNY).
09/27/17
DADA
09/27/17
NO CHANGE
DADA
Huntington Bancshares named top Midwest mid-cap bank at DA Davidson
DA Davidson analyst Kevin K. Reevey says that Huntington Bancshares (HBAN) is one of his "favorite Midwest-based banks as a value play." The analyst says that the economic environment in the company's home markets is strong, while its auto loan credit metrics rank fourth among the country's top 25 auto lenders. He ranks Huntington Bancshares as his second favorite mid-cap bank, trailing only TCF Financial (TCF).
11/15/17
MSCO
11/15/17
NO CHANGE
MSCO
Morgan Stanley says higher SIFI threshold could benefit Comerica, CIT, Zions
After Senate Banking Committee Chairman Mike Crapo proposed a bill in the Senate that would effectively remove the SIFI threshold for banks under $250B, Morgan Stanley analyst Ken Zerbe estimated that banks with $50B-$100B in assets could see a 12% increase in 2020 EPS and a 15% bump in 2021. He sees the largest potential increase at Comerica (CMA), followed by CIT Group (CIT) and Zions Bancorp (ZION). Zerbe projects the least EPS benefit for SunTrust (STI), Regions Financial (RF), Ally Financial (ALLY) and Discover (DFS), he tells investors. Other banks he lists in his note as potentially impacted by SIFI and CCAR changes include Synchrony (SYF), M&T Bank (MTB), KeyCorp (KEY), Fifth Third (FITB), BB&T (BBT), Citizens Financial (CFG) and Huntington Bancshares (HBAN).
09/14/17
BERN
09/14/17
UPGRADE
BERN
Outperform
KeyCorp upgraded to Outperform at Bernstein
As previously reported, Bernstein analyst Kevin St. Pierre upgraded KeyCorp (KEY) to Outperform from Market Perform as he believes there is more likely to be upside to his 2018-2020 estimates than downside. With the year to date underperformance of the stock, the analyst believes valuation is far more attractive than at the start of the year. St. Pierre also upgraded Citizens Financial (CFG) and Huntington Bancshares (HBAN) to Outperform.
KMB Kimberly-Clark

11/02/17
SOCG
11/02/17
UPGRADE
Target $131
SOCG
Buy
Kimberly-Clark upgraded to Buy from Hold at Societe Generale
Societe Generale analyst Lain Simpson upgraded Kimberly-Clark to Buy saying the sell-off in shares is overdone and maintained a $131 price target. The analyst said US price competition is intense and input costs are rising, but these issues are well known and expects the operational recovery to be a medium term story.
12/11/17
12/11/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Kimberly-Clark (KMB) downgraded to Sell from Neutral at Citi with analyst Wendy Nicholson citing "stiff competition" Kimberly-Clark faces "in multiple categories in multiple markets." 2. TSYS (TSS) downgraded to Neutral from Buy at Goldman Sachs with analyst James Schneider citing valuation with the shares approaching his unchanged price target of $80. 3. Paccar (PCAR) downgraded to Neutral from Overweight at JPMorgan with analyst Ann Duignan saying the North American Class 8 truck market is likely to peak in 2018 and Paccar's stock is likely to continue to see multiple compression. 4. Flowserve (FLS) downgraded to Hold from Buy at Stifel with analyst Nathan Jones saying he sees no near-term catalysts given his expectation of orders being flat to down in the fourth quarter. 5. Brixmor (BRX) downgraded to Neutral from Buy at Mizuho. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/11/17
SBSH
12/11/17
DOWNGRADE
Target $113
SBSH
Sell
Kimberly-Clark downgraded to Sell from Neutral at Citi
Citi analyst Wendy Nicholson downgraded Kimberly-Clark to Sell and cut her price target for the shares to $113 from $124. The analyst lowered her estimates for 2018 and 2019 to reflect "stiff competition" Kimberly-Clark faces "in multiple categories in multiple markets." She sees 2018 being a tough year for the company and further downside in the shares.
12/13/17
DBAB
12/13/17
INITIATION
Target $121
DBAB
Hold
Kimberly-Clark initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Steve Powers started Kimberly-Clark with a Hold rating and $121 price target. The analyst believes future competition may pressure the company's volumes and limit its ability to take price.
RMD ResMed

01/23/18
NORL
01/23/18
UPGRADE
NORL
Market Perform
ResMed upgraded to Market Perform from Underperform at Northland
01/23/18
BMOC
01/23/18
NO CHANGE
Target $90
BMOC
Market Perform
ResMed price target raised to $90 from $82 at BMO Capital
BMO Capital analyst Joanne Wuensch raised her price target on ResMed to $90 after a "wow" Q2 earnings report, saying that operating leverage increase for the first time in a long time while SG&A declined. The analyst adds that the company continues to make progress, with visible demand in Airsense 10 CPAP, AirMini CPAP, and N20 and F20 masks; the launch of its Mobi portable oxygen concentrator; and MyAir new patient signups. Wuensch keeps her Market Perform rating on ResMed.
01/23/18
JEFF
01/23/18
NO CHANGE
Target $75
JEFF
Underperform
ResMed margins continue to deteriorate, says Jefferies
Jefferies analyst Anthony Petrone says a 17c tax benefit drove much of ResMed's Q2 beat while the company's margins continue to deteriorate. Further, underlying sleep growth remains "opaque," Petrone tells investors in a post-earnings research note. The analyst views the company's outlook as unclear and keeps an Underperform rating on the shares. He upped his price target for ResMed to $75 from $60.
01/23/18
MACQ
01/23/18
DOWNGRADE
MACQ
Underperform
ResMed downgraded to Underperform from Neutral at Macquarie
Macquarie analyst David Bailey downgraded ResMed to Underperform citing valuation and ongoing ASP declines.
AMTD TD Ameritrade
$55.88

0.71 (1.29%)

01/08/18
LEHM
01/08/18
UPGRADE
Target $68
LEHM
Overweight
TD Ameritrade upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Jeremy Campbell upgraded TD Ameritrade to Overweight and raised his price target for the shares to $68 from $54. Commissions cuts over the next 12 months are a possibility rather than a likelihood, Campbell tells investors in a research note on the U.S. Brokers, Asset Managers & Exchanges sector. The analyst believes TD Ameritrade shares are attractively valued at current levels.
01/04/18
WELS
01/04/18
NO CHANGE
Target $67
WELS
Outperform
TD Ameritrade price target raised to $67 from $56 at Wells Fargo
Wells Fargo analyst Chris Harris raised his price target for TD Ameritrade to $67 from $56 to incorporate the benefits of tax reform as well as higher interest rates. The analyst reiterates an Outperform rating on the shares.
01/16/18
FBCO
01/16/18
NO CHANGE
Target $52
FBCO
Underperform
TD Ameritrade price target raised to $52 from $45 at Credit Suisse
Credit Suisse analyst Craig Siegenthaler raised his price target for TD Ameritrade to $52 from $45 ahead of quarterly results and to include the impacts of U.S. tax reform. The analyst reiterates an Underperform rating on the shares.
01/08/18
GSCO
01/08/18
NO CHANGE
GSCO
Goldman bullish on Brokers into 2018, upgrades Lazard and Stifel
Goldman Sachs analyst Conor Fitzgerald remains bullish on the Brokers and financial service companies heading into 2018. The analyst thinks large-cap mergers and acquisitions could accelerate and financial deals could return. To reflect these trends, Fitzgerald upgraded both Lazard (LAZ) and Stifel Financial (SF) to Buy from Neutral. The analyst prefers E-Trade (ETFC) and Charles Schwab (SCHW) over TD Ameritrade (AMTD) on the belief that commission price cuts are more likely than not in 2018. Further, Fitzgerald views Interactive Brokers' valuation as full and downgraded the shares to Sell from Neutral. Lastly, he sees a more balanced risk/reward for MarketAxess (MKTX) in this low volatility environment and downgraded the shares to Neutral from Buy.
ATI Allegheny Technologies

01/08/18
COWN
01/08/18
UPGRADE
Target $32
COWN
Outperform
Allegheny Technologies upgraded to Outperform at Cowen
As reported previously, Cowen analyst Gautam Khanna upgraded Allegheny Technologies to Outperform from Market Perform. The analyst sees an improved upside estimate revision due to accelerating sales and positive free cash flow prospects. He said the improvements are from the long-term growth positioning the company had previously undertaken. Khanna raised his price target to $32 from $23 on Allegheny Technologies shares.
01/08/18
COWN
01/08/18
UPGRADE
COWN
Outperform
Allegheny Technologies upgraded to Outperform from Market Perform at Cowen
07/26/17
JPMS
07/26/17
UPGRADE
Target $19
JPMS
Neutral
Allegheny Technologies upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Michael Gambardella upgraded Allegheny Technologies to Neutral and raised his price target for the shares to $19 from $14.50 following the company's Q2 results. The analyst believes the company's downside risk is largely understood by the market at current valuation levels.
09/11/17
BOFA
09/11/17
UPGRADE
Target $24
BOFA
Buy
Allegheny Technologies upgraded to Buy from Underperform at BofA/Merrill
BofA/Merrill analyst Timna Tanners upgraded Allegheny Technologies (ATI) two notches to Buy from Underperform and increased its price target to $24 from $16 saying it is poised to benefit from a new jet engine technology cycle. The analyst expects a "sharp" increase in engine margin improvement, and a mix shift towards the engine market, displacing lower margin businesses and said Flat Rolled Products headwinds and other delays are behind it. He sees catalysts over the next six months including the Boeing and Airbus ramping up the 737max and A320neo, retirement of 40% of the Flat Rolled Products workforce over five years, improved commodity values, and market share gains from Arconic's (ARNC) isothermal forge delays.
TSLA Tesla
$351.56

1.54 (0.44%)

01/04/18
MSCO
01/04/18
NO CHANGE
Target $379
MSCO
Equal Weight
Morgan Stanley says Tesla Model 3 target shift 'should not at all be a surprise'
Morgan Stanley analyst Adam Jonas noted that Tesla posted delivery figures for Q4 that topped his forecast for each model line it offers, including the Model 3, adding that he thinks Tesla pushing out its production target of 5,000 Model 3 per week to the end of Q2 "should not at all be a surprise to the market." Jonas said his Q1 Model 3 delivery forecast of 8,000 units implies a pace of less than 700 per week, but Tesla appears to be currently producing the mass-market car at a pace well ahead of that implied in his earnings model. The analyst, who also noted that the company's Q4 deliveries suggest revenue 10% above his prior forecast, maintains an Equal Weight rating on the shares but said he would "buy the dip" in Tesla if the delayed Model 3 ramp causes weakness.
01/04/18
JPMS
01/04/18
NO CHANGE
Target $185
JPMS
Underweight
JPMorgan keeps $185 target on Tesla after production shortfall
JPMorgan analyst Ryan Brinkman reiterates an Underweight rating on Tesla shares with a $185 price target after the company's Model 3 deliveries in Q4 came in at 1,550, well below his 10,000 estimate. The stock in premarket trading is down 3%, or $11.00, to $306.25. The weaker than expected launch is likely the result of too optimistic assumptions on the company's part as regards the ease of manufacturing the Model 3, Brinkman tells investors in a research note titled "Model 3 Ramp Falls Far Short Again - Has Tesla Overestimated its Ease of Manufacture? Reiterate UW." The analyst believes that if the Q3 and Q4 production shortfalls stem from an overestimation of the ease to manufacture, then likely the associated cost to manufacture has been underestimated. He thinks this would reinforce his more bearish outlook on Tesla.
01/08/18
BARD
01/08/18
UPGRADE
Target $152
BARD
Outperform
Albemarle upgraded to Outperform at Baird
As reported previously, Baird analyst Ben Kallo upgraded Albemarle (ALB) to Outperform from Neutral as he sees several upcoming catalysts that could drive the shares higher. Those catalysts include upcoming auto shows, which could display new electric cars that are drivers of lithium demand, potential auto announcements regarding electrification, and an ongoing ramp of Tesla's (TSLA) Model 3. Kallo raised his price target to $152 from $135 on Albemarle shares.
01/23/18
FBCO
01/23/18
NO CHANGE
FBCO
30% solar import tariff positive for First Solar, Tesla, says Credit Suisse
Credit Suisse analyst Michael Weinstein notes that President Trump approved solar import tariffs at 30% for crystalline-silicon solar cells and modules, in-line with expectations. The analyst believes the news is positive for companies exempt from the tariff, notably First Solar (FSLR) and Tesla (TSLA) until now. Conversely, Weinstein expects negative sentiment around Chinese solar manufacturers, such as JinkoSolar (JKS) and JA Solar (JASO), and expects negligible impact to residential solar developers Sunrun (RUN) and Vivint Solar (VSLR).
AAPL Apple
$177.00

-1.46 (-0.82%)

01/23/18
01/23/18
NO CHANGE

IT Hardware industry view double-upgraded to Attractive at Morgan Stanley
Morgan Stanley analyst Katy Huberty upgraded her IT Hardware industry view by two notches, to Attractive from Cautious, stating that she now forecasts 6.6% average revenue growth in 2018. This level of growth would be an acceleration from the past few years and tops the consensus view of 5.9%, noted Huberty. She points to a survey of 100 CIOs that indicates faster planned IT budget growth than three months ago, expectations for faster gross margin expansion, and the benefits of U.S. tax reform to support her view. She favors stocks with enterprise exposure that don't price in a growth acceleration, naming HP Enterprise (HPE) and IBM (IBM) as her top picks. In the same note, Huberty raised her FY18 gross margin view for Apple (AAPL) and increased her price target on the iPhone maker's shares to $205 from $200. This morning, Huberty upgraded HP Enterprise to Overweight and upgraded NetApp (NTAP) and Teradata (TDC), both to Equal Weight from Underweight. She also downgraded HP Inc. (HPQ) to Equal Weight, as previously reported.
01/23/18
BMOC
01/23/18
DOWNGRADE
Target $26
BMOC
Market Perform
Criteo downgraded to Market Perform at BMO Capital on GDPR uncertainty
As reported earlier, BMO Capital analyst Daniel Salmon downgraded Criteo (CRTO) to Market Perform from Outperform and lowered his price target to $26 from $30. Salmon cites a lack of uncertainty on GDPR - General Data Protection Regulation - which goes into effect in E.U. in May of this year. The analyst adds that he "materially underestimated the impact of Apple's (AAPL) Intelligent Tracking Prevention, stating he believes that Criteo will be one of the companies facing the most risk.
01/22/18
01/22/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Neutral from Overweight at Atlantic Equities with analyst James Cordwell citing signs that iPhone demand is beginning to soften and emerging challenges to the smartphone's dominance. 2. General Electric (GE) downgraded to Neutral from Buy at BofA/Merrill with analyst Andrew Obin saying he expects management to lower 2018 guidance when it reports fourth quarter earnings on Wednesday. 3. American Express (AXP) downgraded to Neutral from Buy at Guggenheim with analyst Jeff Cantwell citing CCAR risk in 2018, the fact that its balance sheet is liability-sensitive, and the assumption that the company's provision expense will be significantly higher than expected in fiscal 2018. 4. Eli Lilly (LLY) downgraded to Underperform from Neutral at Credit Suisse with analyst Vamil Divan saying he does not believe Lilly is on track to hit its mid-term guidance of 5% annual sales growth from 2015-2020. 5. Symantec (SYMC) downgraded to Neutral from Outperform at Credit Suisse with analyst Brad Zelnick saying accelerating enterprise expectations do not square with mixed channel sentiment. The analyst also lowered his price target on the shares to $30 from $36. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/22/18
01/22/18
DOWNGRADE
Target $190

Neutral
Apple downgraded on worries about current, future iPhones at Atlantic Equities
As previously reported, Atlantic Equities analyst James Cordwell downgraded Apple to Neutral from Overweight citing signs that iPhone demand is beginning to soften and emerging challenges to the smartphone's dominance. While Cordwell thinks robust iPhone demand and a favorable iPhone X mix in the December quarter, or Apple's fiscal Q1, make quarterly upside likely, he also fears much of this strength was pull forward of demand and sees a risk that Q2 guidance will fall short, he tells investors. Cordwell keeps his $190 price target on Apple shares.
PG Procter & Gamble

01/16/18
GSCO
01/16/18
UPGRADE
Target $88
GSCO
Neutral
Procter & Gamble upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Jason English upgraded Procter & Gamble to Neutral and raised his price target for the shares to $88 from $83. The analyst no longer sees enough downside to estimates to drive material underperformance for the stock. he admits his expectation of a negative estimate revision cycle has failed to materialize.
01/16/18
01/16/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) upgraded to Buy from Neutral at Nomura Instinet with analyst Romit Shah saying with Broadcom's (AVGO) hostile takeover attempt now analogous to a "gun to the head," Qualcomm management is likely to more aggressively focus on driving shareholder value in order to remain a standalone franchise. 2. Twitter (TWTR) upgraded to Buy from Sell at Aegis with analyst Victor Anthony saying he believes 2018 will be an inflection point in owned and operated advertising for Twitter and he sees a return to double-digit growth in that area in 2019. 3. Procter & Gamble (PG) upgraded to Neutral from Sell at Goldman Sachs with analyst Jason English saying he no longer sees enough downside to estimates to drive material underperformance for the stock. 4. Northrop Grumman (NOC) and Curtiss-Wright (CW) were upgraded to Outperform from Market Perform at Wells Fargo. 5. Ciena (CIEN) was upgraded to Buy from Neutral at Goldman Sachs, while Adtran (ADTN) was upgraded to Neutral from Sell. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/27/17
JEFF
12/27/17
NO CHANGE
JEFF
Nielsen shows improved two-week sales trends, says Jefferies
Jefferies analyst Kevin Grundy says two-week sales growth in U.S. Nielsen channels improved sequentially for key home and personal care companies Colgate-Palmolive (CL), Church & Dwight (CHD) and Clorox (CLX), as well as beverage companies Monster Beverage (MNST), Coca-Cola (KO) and Dr Pepper Snapple (DPS). While overall growth remains tepid, sequential improvement in December for consumer spending, including staples, has been more upbeat, Grundy tells investors in a research note titled "Party Like It's 1999? Not Quite, But US Nielsen HPC/Bevs 2-Week Data Improves." The analyst favors shares of Church & Dwight, Procter & Gamble (PG), Dr Pepper and Monster.
12/13/17
DBAB
12/13/17
INITIATION
Target $101
DBAB
Buy
Procter & Gamble initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Steve Powers started Procter & Gamble with a Buy rating and $101 price target. The company is well positioned after "finally" catching up with market realities," the analyst contends. He views the risk/reward as attractive at current share levels.
ADMS Adamas Pharmaceuticals
$40.79

2.6 (6.81%)

12/13/17
COWN
12/13/17
NO CHANGE
Target $55
COWN
Outperform
Adamas Pharmaceuticals named a best idea for 2018 at Cowen
Cowen analyst Ken Cacciatore views shares of Adamas Pharmaceuticals as "meaningfully undervalued" at current levels. He calls the stock a best idea for 2018 and keeps an Outperform rating on the name with a $55 price target. The analyst is confident that Gocovri, which is now on the market, will find a "significant place" in the Parkinson's disease treatment paradigm. He says Adamas has successfully developed an extended release amantadine for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease.
11/29/17
NORL
11/29/17
INITIATION
Target $70
NORL
Outperform
Adamas Pharmaceuticals initiated with an Outperform at Northland
Northland analyst Carl Byrnes initiated Adamas Pharmaceuticals with an Outperform and $70 price target. The analyst said Adamas' GOCOVRI is a breakthrough in treating Parkinson's patients that have developed dyskinesia as a result of long-term exposure to levodopa therapy and sees peak sales exceeding $750M.
10/30/17
10/30/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sotheby's (BID) initiated with a Buy at Aegis. 2. Alnylam (ALNY) initiated with a Buy at FBR Capital. 3. Adamas Pharmaceuticals (ADMS) initiated with an Outperform at Evercore ISI. 4. Vipshop (VIPS) initiated with a Neutral at UBS. 5. Rhythm Pharmaceuticals (RYTM) initiated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/19/17
PIPR
12/19/17
NO CHANGE
Target $52
PIPR
Overweight
Adamas Pharmaceuticals price target raised to $52 from $35 at Piper Jaffray
Piper Jaffray analyst David Amsellem raised his price target for Adamas Pharmaceuticals to $52 saying his survey of 27 neurologists who treat a significant number of patients with epilepsy yielded "encouraging early feedback" on ADS-4101. The feedback suggests a relatively high degree of enthusiasm for a next-generation form of lacosamide, Amsellem tells investors in a research note. He views ADS-4101 as a "relatively underappreciated longer-term value driver" for Adamas and keeps an Overweight rating on the shares.
GPRO GoPro
$6.30

0.01 (0.16%)

01/23/18
01/23/18
DOWNGRADE
Target $5

Underweight
GoPro downgraded to Underweight on limited strategic value at Morgan Stanley
As previously reported, Morgan Stanley Yuuji Anderson downgraded GoPro to Underweight from Equal Weight, arguing that the market is giving too much credit to the company for its strategic value. Improving action camera demand hinges on meaningful improvements in usability, and without acceleration in that area Yuuji thinks negative trends are more likely to continue into 2019, weighing on earnings and GoPro's potential strategic value, he tells investors in a note partially titled "A Long Year Ahead." The analyst cut his price target on GoPro to $5 from $9.50.
01/23/18
MSCO
01/23/18
DOWNGRADE
MSCO
Underweight
GoPro downgraded to Underweight from Equal Weight at Morgan Stanley
01/08/18
01/08/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. GoPro (GPRO) downgraded to Neutral from Buy at Longbow with analyst Joe Wittine saying his channel checks confirmed the holidays missed the company's plan and late quarter $100 price cuts were not enough to save the quarter. 2. Snap (SNAP) downgraded to Hold from Buy at Jefferies with analyst Brent Thill saying he continues to have optimism around Snap's platform, but believes "fundamental execution needs to be shown" before he can be more positive on the name. 3. Cirrus Logic (CRUS) downgraded to Sector Weight from Overweight at KeyBanc with analyst John Vinh citing his "disappointment" with the current iPhone cycle and the lack of meaningful content gains until 2019. 4. Pandora (P) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Benjamin Swinburne noting that the company's core free product has not evolved meaningfully and faces continued innovation by Spotify, Apple (AAPL) and Amazon (AMZN) while also being pressured by free music available on Google's (GOOG) YouTube. 5. GrubHub (GRUB) downgraded to Neutral from Outperform at Wedbush with analyst Aaron Turner saying that while he continues to like the company's market opportunity and competitive positioning, the current peak valuation of shares accurately reflects these positive dynamics. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/09/18
SBSH
01/09/18
NO CHANGE
Target $7
SBSH
Neutral
GoPro price target lowered to $7 from $8.50 at Citi
Citi analyst Stanley Kovler lowered his price target for GoPro shares to $7 citing weaker revenue growth and earnings power prospects than previously assumed. GoPro's pricing power appears more limited following yesterday's news, Kovler tells investors in a research note. The analyst says new layoffs in the Karma division "cut off another possible growth avenue and create further challenges for a turnaround." He keeps a Neutral rating on the stock.
TWTR Twitter

01/19/18
VERF
01/19/18
INITIATION
VERF
Negative
Twitter initiated with a Negative due to lack of ad growth at Vertical Group
01/18/18
STFL
01/18/18
NO CHANGE
Target $21
STFL
Hold
Twitter coverage transferred with a Hold at Stifel
Stifel analyst John Egbert took over coverage of Twitter with a Hold rating on the shares with a $21 price target. The analyst believes better 2018 advertising results are already reflected in the stock price. He wants to see improving monthly active user growth and a stabilization of advertising pricing before getting more constructive on the name.
01/16/18
01/16/18
UPGRADE
Target $30

Buy
Twitter upgraded to Buy with $30 target at Aegis
As previously reported, Aegis analyst Victor Anthony upgraded Twitter (TWTR) two notches, to Buy from Sell, and set a $30 price target on the stock. Anthony believes 2018 will be an inflection point in owned and operated advertising for Twitter and he sees a return to double-digit growth in that area in 2019. He also sees the potential for improving monthly average user growth, sustained double-digit daily active user growth and thinks the stock could be included in the S&P 500 at some point. Additionally, Anthony sees Facebook's (FB) decision to de-emphasize public content making Twitter a more valuable resource for video and news, making it an even more appealing takeover candidate, he tells investors.

TODAY'S FREE FLY STORIES

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

, ABBV

AbbVie

$118.60

3.7 (3.22%)

04:55
02/18/18
02/18
04:55
02/18/18
04:55
Conference/Events
American Academy of Dermatology holds annual meeting »

2018 AAD Annual Meeting…

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

AGN

Allergan

$164.04

-0.43 (-0.26%)

ALIOF

Actelion

ARDX

Ardelyx

$5.80

-0.2 (-3.33%)

BVX

Bovie Medical

$2.50

0.1 (4.17%)

CELG

Celgene

$95.26

-0.88 (-0.92%)

CUTR

Cutera

$48.40

-2.1 (-4.16%)

HSIC

Henry Schein

$69.52

1.14 (1.67%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

LLY

Eli Lilly

$78.97

0.95 (1.22%)

LMNS

Lumenis

MYGN

Myriad Genetics

$32.81

-0.57 (-1.71%)

MYL

Mylan

$42.14

0.49 (1.18%)

NVS

Novartis

$86.91

0.23 (0.27%)

PFE

Pfizer

$36.26

0.55 (1.54%)

PG

Procter & Gamble

$82.60

0.19 (0.23%)

PRGO

Perrigo

$89.55

-0.1 (-0.11%)

REGN

Regeneron

$332.15

-1.03 (-0.31%)

SNY

Sanofi

$39.91

0.19 (0.48%)

UL

Unilever; also tag UN

$53.55

-0.22 (-0.41%)

UN

Unilever; also tag UL

$54.59

-0.15 (-0.27%)

WTKWY

Wolters Kluwer

$49.37

-0.27 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 21

    Feb

  • 26

    Feb

  • 27

    Feb

  • 02

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 12

    Mar

  • 12

    Mar

  • 25

    Mar

  • 29

    Mar

  • 04

    Apr

  • 23

    Apr

  • 23

    Apr

  • 02

    May

  • 03

    May

  • 17

    May

  • 30

    May

  • 13

    Nov

MRVL

Marvell

$22.68

-0.06 (-0.26%)

, CAVM

Cavium

$87.16

-0.09 (-0.10%)

14:55
02/17/18
02/17
14:55
02/17/18
14:55
Conference/Events
Cavium to host special shareholder meeting »

Special Shareholder…

MRVL

Marvell

$22.68

-0.06 (-0.26%)

CAVM

Cavium

$87.16

-0.09 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 08

    Mar

CAVM

Cavium

$87.16

-0.09 (-0.10%)

, MRVL

Marvell

$22.68

-0.06 (-0.26%)

14:51
02/17/18
02/17
14:51
02/17/18
14:51
Conference/Events
Marvell to host special shareholder meeting »

Special Shareholder…

CAVM

Cavium

$87.16

-0.09 (-0.10%)

MRVL

Marvell

$22.68

-0.06 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

DEL

Deltic Timber

$98.45

1.77 (1.83%)

, PCH

Potlatch

$54.75

0.75 (1.39%)

14:45
02/17/18
02/17
14:45
02/17/18
14:45
Conference/Events
Potlatch to host special shareholder meeting »

Special Shareholder…

DEL

Deltic Timber

$98.45

1.77 (1.83%)

PCH

Potlatch

$54.75

0.75 (1.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

PCH

Potlatch

$54.75

0.75 (1.39%)

, DEL

Deltic Timber

$98.45

1.77 (1.83%)

14:42
02/17/18
02/17
14:42
02/17/18
14:42
Conference/Events
Deltic Timber to host special shareholder meeting »

Special shareholder…

PCH

Potlatch

$54.75

0.75 (1.39%)

DEL

Deltic Timber

$98.45

1.77 (1.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$20.42

0.67 (3.39%)

09:31
02/17/18
02/17
09:31
02/17/18
09:31
Periodicals
Snap CEO sold $50M in stock this week, Recode reports »

Snap CEO Evan Spiegel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 07

    Mar

GLPG

Galapagos NV

$115.33

-1.4 (-1.20%)

, MPSYY

MorphoSys

$46.29

1.29 (2.87%)

09:27
02/17/18
02/17
09:27
02/17/18
09:27
Hot Stocks
Galapagos NV, MorphoSys present results from Phase 1 study with MOR106 in AD »

Galapagos NV (GLPG) and…

GLPG

Galapagos NV

$115.33

-1.4 (-1.20%)

MPSYY

MorphoSys

$46.29

1.29 (2.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$360.53

-0.47 (-0.13%)

09:22
02/17/18
02/17
09:22
02/17/18
09:22
Hot Stocks
Lockheed Martin receives Freedom-variant FFG conceptual design contract »

The U.S. Navy awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 07

    Mar

  • 30

    May

UAA

Under Armour; also tag UA

$17.36

-1.05 (-5.70%)

, UA

Under Armour; also tag UAA

$15.78

-0.76 (-4.59%)

09:11
02/17/18
02/17
09:11
02/17/18
09:11
Periodicals
Bears, bulls battle over Under Armour, Barron's says »

In a follow-up story,…

UAA

Under Armour; also tag UA

$17.36

-1.05 (-5.70%)

UA

Under Armour; also tag UAA

$15.78

-0.76 (-4.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOV

Hovnanian

$2.24

0.12 (5.66%)

09:04
02/17/18
02/17
09:04
02/17/18
09:04
Periodicals
Hovnanian stock too cheap to ignore, Barron's says »

Hovnanian Enterprises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$114.68

-0.83 (-0.72%)

, JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

09:00
02/17/18
02/17
09:00
02/17/18
09:00
Periodicals
JPMorgan, Walmart cash flow yields exceed dividend yields, Barron's says »

The cash flow yields of…

JPM

JPMorgan

$114.68

-0.83 (-0.72%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

WMT

Walmart

$104.78

1.55 (1.50%)

PFE

Pfizer

$36.26

0.55 (1.54%)

CSCO

Cisco

$44.33

0.25 (0.57%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

PEP

PepsiCo

$111.06

0.09 (0.08%)

MMM

3M

$236.67

1.8 (0.77%)

BMY

Bristol-Myers

$68.96

-0.02 (-0.03%)

UTX

United Technologies

$129.26

-0.74 (-0.57%)

TXN

Texas Instruments

$104.47

-0.1 (-0.10%)

ABT

Abbott

$60.17

0.67 (1.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Feb

  • 19

    Feb

  • 20

    Feb

  • 21

    Feb

  • 23

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 05

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 13

    Mar

  • 29

    Mar

  • 04

    Apr

  • 13

    Apr

  • 30

    May

  • 14

    Jul

  • 12

    Oct

GOOGL

Alphabet Class A

$1,095.50

4.14 (0.38%)

, GOOG

Alphabet

$1,094.80

5.28 (0.48%)

08:56
02/17/18
02/17
08:56
02/17/18
08:56
Periodicals
Alphabet, Citi well positioned for later stages of market rally, Barron's says »

It is time for investors…

GOOGL

Alphabet Class A

$1,095.50

4.14 (0.38%)

GOOG

Alphabet

$1,094.80

5.28 (0.48%)

C

Citi

$76.82

-0.26 (-0.34%)

CMI

Cummins

$165.60

0.58 (0.35%)

LRCX

Lam Research

$187.91

2.2 (1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 18

    Mar

  • 28

    Mar

  • 29

    Mar

  • 30

    May

GE

General Electric

$15.05

0.2 (1.35%)

08:48
02/17/18
02/17
08:48
02/17/18
08:48
Periodicals
General Electric stock could drop another 10%, Barron's says »

General Electric lost $6B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEC

Jacobs Engineering

$63.19

-0.52 (-0.82%)

, VMC

Vulcan Materials

$126.57

-6.9 (-5.17%)

08:32
02/17/18
02/17
08:32
02/17/18
08:32
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

JEC

Jacobs Engineering

$63.19

-0.52 (-0.82%)

VMC

Vulcan Materials

$126.57

-6.9 (-5.17%)

PWR

Quanta Services

$35.07

0.24 (0.69%)

EXP

Eagle Materials

$102.75

-3.83 (-3.59%)

FLR

Fluor

$57.63

-0.22 (-0.38%)

USCR

U.S. Concrete

$78.00

-1.4 (-1.76%)

ACM

Aecom

$35.36

0.08 (0.23%)

CBI

CB&I

$18.71

0.04 (0.21%)

GVA

Granite Construction

$60.36

2.69 (4.66%)

CAT

Caterpillar

$156.29

-3.69 (-2.31%)

MLM

Martin Marietta

$216.25

-6.34 (-2.85%)

V

Visa

$121.85

-0.43 (-0.35%)

AA

Alcoa

$47.36

-0.21 (-0.44%)

ARNC

Arconic

$25.36

0.14 (0.56%)

CENX

Century Aluminum

$24.12

1.85 (8.31%)

X

U.S. Steel

$44.75

5.76 (14.77%)

STLD

Steel Dynamics

$49.40

2.26 (4.79%)

AKS

AK Steel

$5.96

0.72 (13.74%)

CLF

Cleveland-Cliffs

$7.92

0.55 (7.46%)

NUE

Nucor

$68.54

2.96 (4.51%)

MT

ArcelorMittal

$36.48

1.19 (3.37%)

TKR

Timken

$45.00

-0.08 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 23

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 01

    Mar

  • 14

    Mar

  • 23

    May

  • 30

    May

04:55
02/17/18
02/17
04:55
02/17/18
04:55
Conference/Events
Cambridge Healthtech Institute to hold a conference »

Molecular Med Tri-Con…

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

, ABBV

AbbVie

$118.60

3.7 (3.22%)

04:55
02/17/18
02/17
04:55
02/17/18
04:55
Conference/Events
American Academy of Dermatology holds annual meeting »

2018 AAD Annual Meeting…

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

AGN

Allergan

$164.04

-0.43 (-0.26%)

ALIOF

Actelion

ARDX

Ardelyx

$5.80

-0.2 (-3.33%)

BVX

Bovie Medical

$2.50

0.1 (4.17%)

CELG

Celgene

$95.26

-0.88 (-0.92%)

CUTR

Cutera

$48.40

-2.1 (-4.16%)

HSIC

Henry Schein

$69.52

1.14 (1.67%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

LLY

Eli Lilly

$78.97

0.95 (1.22%)

LMNS

Lumenis

MYGN

Myriad Genetics

$32.81

-0.57 (-1.71%)

MYL

Mylan

$42.14

0.49 (1.18%)

NVS

Novartis

$86.91

0.23 (0.27%)

PFE

Pfizer

$36.26

0.55 (1.54%)

PG

Procter & Gamble

$82.60

0.19 (0.23%)

PRGO

Perrigo

$89.55

-0.1 (-0.11%)

REGN

Regeneron

$332.15

-1.03 (-0.31%)

SNY

Sanofi

$39.91

0.19 (0.48%)

UL

Unilever; also tag UN

$53.55

-0.22 (-0.41%)

UN

Unilever; also tag UL

$54.59

-0.15 (-0.27%)

WTKWY

Wolters Kluwer

$49.37

-0.27 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 21

    Feb

  • 26

    Feb

  • 27

    Feb

  • 02

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 12

    Mar

  • 12

    Mar

  • 25

    Mar

  • 29

    Mar

  • 04

    Apr

  • 23

    Apr

  • 02

    May

  • 03

    May

  • 17

    May

  • 30

    May

  • 13

    Nov

MIDD

Middleby

$135.00

1.94 (1.46%)

18:01
02/16/18
02/16
18:01
02/16/18
18:01
Hot Stocks
Middleby acquires Hinds-Bock Corporation, terms not disclosed »

Middleby announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.14

0.14 (0.38%)

, TWX

Time Warner

$95.37

0.38 (0.40%)

17:37
02/16/18
02/16
17:37
02/16/18
17:37
Periodicals
Breaking Periodicals news story on AT&T, Time Warner »

Judge says to rule on …

T

AT&T

$37.14

0.14 (0.38%)

TWX

Time Warner

$95.37

0.38 (0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 23

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 05

    Mar

CARS

Cars.com

$29.27

0.33 (1.14%)

17:31
02/16/18
02/16
17:31
02/16/18
17:31
Hot Stocks
Breaking Hot Stocks news story on Cars.com »

Starboard raises stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONTX

Onconova

$1.07

0.01 (0.94%)

17:29
02/16/18
02/16
17:29
02/16/18
17:29
Hot Stocks
683 Capital reports 21.8% stake in Onconova, says shares undervalued »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$224.19

-1.21 (-0.54%)

17:26
02/16/18
02/16
17:26
02/16/18
17:26
Hot Stocks
General Dynamics awarded $148.9M government contract modification »

General Dynamics Land…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATRS

Antares Pharma

$2.39

0.04 (1.70%)

17:25
02/16/18
02/16
17:25
02/16/18
17:25
Hot Stocks
Breaking Hot Stocks news story on Antares Pharma »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HII

Huntington Ingalls

$265.70

10.31 (4.04%)

17:25
02/16/18
02/16
17:25
02/16/18
17:25
Hot Stocks
Huntington Ingalls awarded $1.43B government contract modification »

Huntington Ingalls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

DIT

AMCON Distributing

$87.50

0.13 (0.15%)

17:24
02/16/18
02/16
17:24
02/16/18
17:24
Hot Stocks
Breaking Hot Stocks news story on AMCON Distributing »

Hale Partnership reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$41.09

-0.76 (-1.82%)

, TSLA

Tesla

$335.49

1.425 (0.43%)

17:11
02/16/18
02/16
17:11
02/16/18
17:11
Periodicals
Chevy Bolt sales bolstered by Tesla delays, tax credit worries, Reuters says »

Certain potential buyers…

GM

General Motors

$41.09

-0.76 (-1.82%)

TSLA

Tesla

$335.49

1.425 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.